RespireRx Pharmaceuticals Inc (RSPI)

[drfreely]

"ambiguous results" I can't help but go back to this Tran business, though it seems forgotten already. At the very least his leaving had to have made data set analysis more time consuming. I know the desire to join with the A-Team of Piskorski, Barberich, Manthis, and Pappafotopoulous and develop EB1010 in a "real" trial had to influence his decision, but couldn't his ability to forsee not so conclusive trial results based on years of clinical trial experience in both pharma and academia have influenced his decision, made so close to the conclusion of SA?
There may be another "good thing" about weak SA other than freeing up CX-1739. It may be the final straw that forces management to begin serious talks about a fire sale of all assets, since ADHD cannot be developed without funding sources that will not materialize.